Medigene AG
Ad hoc-Service: MediGene AG english
Ad hoc announcement processed and transmitted by DGAP.
The issuer has the sole responsibility of this announcement.
——————————————————————————–
MEDIGENE RECEIVES EUROPEAN MARKETING RIGHTS FOR LATE STAGE PROSTATE CANCER DRUG
LEUPROGEL(TM)
Agreement pushes MediGene closer to commercialization of first drug
Martinsried, Germany (April 5, 2001) The international biopharmaceutical
company MediGene AG (NMarkt: MDG) announced today that it has entered into an
exclusive European marketing agreement with Atrix Laboratories, Inc. for three
products based on Leuprogel(TM) to treat advanced prostate cancer. Atrix
Laboratories, Inc. (Nasdaq NM: ATRX) is an emerging specialty pharmaceutical
company focused on advanced drug delivery.
The clinical trials for the Leuprogel(TM) One Month product have been
successfully completed with encouraging results and a new drug application
(NDA) has been submitted to the FDA. The phase 3 trials for the three-month and
four-month application of Leuprogel(TM) are in progress and Atrix expects to
submit an NDA for the Leuprogel Three-Month product later this year (for
additional information on Leuprogel(TM) and the clinical trials please refer to
the Atrix Laboratories, Inc. Web site at http://www.atrixlabs.com).
Under the terms of the agreement, MediGene will provide all resources needed to
conduct clinical research and regulatory activities associated with seeking
European marketing approvals. The agreement includes an option for MediGene to
develop and market Leuprogel(TM) for additional indications.
Atrix will receive license fees and payments for certain clinical, regulatory
and sales milestones which could amount to approximately US$ 20 million
including the purchase of US$ 4 million in shares of Atrix’s common stock. In
addition, Atrix will receive royalty payments based on MediGene’s sales of the
Leuprogel products and will manufacture Leuprogel for MediGene.
For further information please contact:
MediGene AG email: investor@medigene.de
fax: ++49 – 89 – 89 56 32-20
Christine Bohner, Public Relations phone: ++49 – 89 – 89 56 32-16
Michael Nettersheim, Investor Relations phone: ++49 – 89 – 89 56 32-46
end of ad hoc announcement, (c) DGAP 05.04.2001
——————————————————————————–
WKN: 502090; Index: NEMAX- 50
Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf,
Hamburg, Hannover, München und Stuttgart
050842 Apr 01
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found